Failure to Diagnose Cancer: Lost Chance Doctrine + Damages Calculation

By John Mahoney · May 2026 · 15 min read

Failure to diagnose cancer is one of the most common medical malpractice claim categories and one of the most analytically complex. The patient presents with symptoms that should have led to a diagnostic workup, the workup is delayed or omitted, the cancer is eventually diagnosed at a more advanced stage, and the question becomes how to characterize the harm caused by the delay. Unlike acute injury cases where the harm is immediate and visible, delayed cancer diagnosis involves a probabilistic injury: the patient's prognosis is worse than it would have been with timely diagnosis, but cancer outcomes are inherently uncertain even with optimal care.

This guide walks plaintiff attorneys through the standard-of-care framework for cancer diagnosis, the lost chance doctrine that addresses probabilistic harm, the stage-based damages calculation, and the evidence development strategy that turns a delayed diagnosis into a viable case.

Disclaimer: This guide is for informational purposes only and does not constitute legal advice. Cancer diagnostic standards, lost chance doctrine, and damages frameworks vary by jurisdiction and cancer type. Always consult qualified oncology experts and verify current standards before relying on any framework discussed here.

The Standard-of-Care Framework

Cancer diagnosis cases typically fall into one of three patterns, each with its own standard-of-care analysis.

Failure to screen

The first pattern is failure to perform recommended screening. Established cancer screening recommendations exist for breast cancer (mammography), colon cancer (colonoscopy, FIT, and other modalities), cervical cancer (Pap and HPV testing), lung cancer (low-dose CT in high-risk populations), and prostate cancer (PSA, though this is controversial). Each screening program has age, risk-factor, and interval criteria.

Failure-to-screen cases require establishing that the patient met the criteria for screening, that the physician failed to offer or perform the screening, and that the cancer would have been detected at an earlier stage with screening. Defense arguments often focus on the patient's role in declining or not following through with screening, the controversial status of some screening recommendations, and the limits of screening sensitivity.

Failure to evaluate symptoms

The second pattern is failure to appropriately evaluate symptoms suggestive of cancer. The patient presents with concerning symptoms — persistent cough, hematuria, rectal bleeding, unintentional weight loss, lumps, abnormal bleeding — and the physician fails to perform appropriate evaluation. This is the most common pattern.

Symptom-evaluation cases require establishing what the symptom should have prompted (additional history, examination, imaging, laboratory testing, referral), what was actually done, and what diagnostic pathway would have led to earlier detection. The standard-of-care expert testifies to the appropriate workup for the symptom presentation.

Failure to follow up abnormal findings

The third pattern is failure to act on abnormal findings already in the record. The radiologist identified a suspicious nodule on a chest CT performed for other reasons. The pathologist noted atypical cells on a biopsy. The laboratory flagged a markedly elevated tumor marker. These abnormal findings require follow-up that sometimes does not occur.

Follow-up failure cases are often the strongest in this category because the abnormal finding is documented in the record. The deviation is not a failure to consider a diagnosis but a failure to act on information already known. Tracking systems for abnormal findings, communication failures between specialists, and patient-notification failures all produce follow-up gaps.

The Causation Problem

Causation is the central challenge in delayed cancer diagnosis cases. Two questions structure the analysis:

1. Would timely diagnosis have changed the cancer's course?
2. How much worse is the patient's prognosis because of the delay?

Both questions involve probabilistic reasoning. Cancer outcomes are inherently uncertain. Patients diagnosed at stage I may still die of cancer; patients diagnosed at stage IV may achieve long remissions. The causation analysis must engage this uncertainty rather than asserting certainty that delay made the difference.

Stage migration as the analytic frame

The most common framing of delayed-diagnosis causation is stage migration. The plaintiff's theory is that timely diagnosis would have caught the cancer at an earlier stage, and the earlier stage carries a substantially better prognosis. The defense response is often that the cancer would have progressed similarly regardless of when it was diagnosed.

The strength of the stage migration theory depends on:

• The specific cancer type and its growth kinetics
• The delay duration relative to the cancer's typical doubling time
• The stage at delayed diagnosis and the inferred stage at timely diagnosis
• The stage-specific survival statistics for the cancer type
• The treatment differences between stages

The all-or-nothing rule

The traditional causation rule in tort law is the more-likely-than-not standard. The plaintiff must prove that the negligence more likely than not caused the harm. Applied to delayed cancer diagnosis, this rule excludes recovery in cases where the patient's pre-delay survival probability was less than 50%, because the plaintiff cannot show that timely diagnosis more likely than not would have prevented death.

Under the all-or-nothing rule, a patient with a delayed lung cancer diagnosis whose stage I survival probability was 60% can recover full wrongful death damages if the delay reduced survival to a lesser probability. A patient with the same diagnosis whose stage I survival was 40% cannot recover at all, because the plaintiff cannot prove more likely than not that timely diagnosis would have prevented death.

The all-or-nothing rule produces results that many legal observers find troubling, particularly because it treats the patient with worse baseline prognosis as having no compensable harm.

The Lost Chance Doctrine

The lost chance doctrine is the principal alternative to the all-or-nothing rule. Under lost chance, the plaintiff can recover for the reduction in survival probability caused by the delay, even when the pre-delay probability was below 50%. The damages are calculated as the value of the loss — typically full damages multiplied by the percentage reduction in survival probability.

State adoption

States are split on lost chance. A substantial number have adopted the doctrine in some form, often through judicial decisions following the influential reasoning in [STATE CASE — attorney to verify]. Other states retain the all-or-nothing rule. Some states have intermediate doctrines that allow lost chance recovery in limited circumstances.

The doctrinal landscape continues to evolve. Verify the current rule in any jurisdiction before relying on lost chance analysis in case evaluation.

Lost chance damages calculation

Where lost chance applies, the damages calculation has a defined structure. Suppose the patient's survival probability with timely diagnosis would have been 60%, and the actual survival probability with delayed diagnosis is 30%. The lost chance is 30 percentage points. If full wrongful death damages would be $2 million, the lost chance recovery is $2 million times 30%, or $600,000.

The calculation requires reliable evidence of the survival probabilities at both points in time. Stage-specific survival statistics from cancer registries provide the evidence base. Expert oncology testimony characterizes the patient's specific position within the population statistics.

Lost chance in non-fatal outcomes

Lost chance doctrine can also apply to non-fatal outcomes — the loss of opportunity for cure, the loss of less invasive treatment, the loss of better quality of life during remaining life. The damages calculation extends beyond mortality to morbidity differences across stages.

Common Cancer Types in Litigation

Breast cancer

Breast cancer cases often involve failure to interpret mammograms, failure to perform appropriate diagnostic imaging for palpable masses, and failure to follow up suspicious findings. Stage-specific survival differences are substantial, particularly between stage I/II and stage III/IV. Damages calculations rely on well-developed registry data.

Colon cancer

Colon cancer cases involve failure to screen at appropriate age, failure to evaluate symptoms (rectal bleeding, change in bowel habits, weight loss), and failure to follow up positive screening results. Colonoscopy quality issues including incomplete examinations and inadequate polyp removal are subjects of litigation. Stage-based survival differences are dramatic.

Lung cancer

Lung cancer cases involve failure to evaluate suspicious imaging findings, failure to screen high-risk populations, and failure to evaluate persistent respiratory symptoms in smokers. Lung cancer's aggressive growth kinetics often produce strong delay-related stage migration arguments.

Prostate cancer

Prostate cancer cases involve failure to perform PSA screening (controversial), failure to evaluate elevated PSA values, and failure to follow up suspicious digital rectal examination findings. The natural history of prostate cancer is variable, complicating causation analysis in some cases.

Skin cancer (melanoma)

Melanoma cases involve failure to biopsy suspicious lesions and failure to recognize melanoma's characteristic features. Stage-based survival differences are dramatic, particularly between local disease and metastatic disease.

Cervical cancer

Cervical cancer cases involve failure to perform appropriate screening, failure to follow up abnormal Pap results, and failure to perform appropriate colposcopy and biopsy.

Evidence Development

Reconstructing the timeline

The diagnostic timeline is the centerpiece of the case. Extract every visit, every symptom, every examination finding, every test ordered, every test result, every imaging study, and every pathology report. Construct a unified chronology showing what was known when and what was done in response.

Identifying the deviation points

Within the timeline, identify the specific points where the standard of care required additional evaluation that did not occur. These deviation points become the alternative timeline — what would have happened with appropriate care.

Establishing the alternative diagnosis date

The plaintiff must establish when the cancer would have been diagnosed with timely workup. Expert testimony typically traces a hypothetical pathway from the missed evaluation point through standard diagnostic workup to a diagnosis date.

Establishing the stage at the alternative diagnosis date

The cancer's growth kinetics support inference about its stage at the alternative diagnosis date. Tumor doubling times for various cancer types are well-studied. Expert oncology testimony characterizes the inferred stage at the alternative timeline point.

Survival comparison

Compare stage-specific survival statistics for the inferred earlier stage and the actual diagnosed stage. Population data from cancer registries provides the statistical baseline; expert testimony characterizes the patient's position within the population.

Damages Beyond Lost Chance

Even under all-or-nothing causation rules, several damage categories can support recovery in delayed cancer diagnosis cases.

Additional treatment burden

A patient diagnosed at a later stage often requires more aggressive treatment — additional surgery, more extensive chemotherapy, radiation, or combinations. The additional treatment burden is a compensable harm even if the survival outcome would have been the same.

Quality of life differences

Quality of life differs across cancer stages. A patient living with metastatic disease has different functional status, symptom burden, and life experience than a patient cured at early stage. Quality-adjusted life-year analysis quantifies these differences.

Economic damages

Lost earnings during prolonged treatment, lost earnings during reduced functional periods, and additional medical expenses are all economic damages that may be recoverable independent of survival impact.

Pain and suffering

The pain and suffering of more advanced cancer, more aggressive treatment, and longer cancer experience are compensable in any jurisdiction recognizing non-economic damages.

The Defense Playbook

Cancer diagnosis defendants typically pursue several themes plaintiff counsel should anticipate.

The cancer was aggressive regardless

Defense oncology experts argue that the patient's specific cancer was biologically aggressive and would have produced poor outcomes even with timely diagnosis. The argument is supported by tumor biomarkers, histologic features, and molecular profiles where available.

The patient was non-compliant

Defense counsel argue that the patient failed to follow recommendations, missed appointments, or declined recommended workup. Comparative fault arguments seek to reduce or eliminate recovery based on patient conduct.

The screening was not standard of care

Defense counsel argue that the screening recommendations the plaintiff invokes are controversial or not universally accepted. The argument is particularly common in prostate cancer cases and in cases involving screening near the boundaries of age recommendations.

Causation is speculative

Defense counsel argue that the alternative timeline is speculative — that the diagnosis date, the inferred earlier stage, and the survival difference are all built on assumptions. The plaintiff response requires careful expert testimony grounding each step in population data and specific patient factors.

Bottom Line

Failure to diagnose cancer cases are analytically complex but doctrinally well-developed. The standard-of-care framework distinguishes failure to screen, failure to evaluate symptoms, and failure to follow up abnormal findings. The causation analysis turns on stage migration and survival probability differences. The lost chance doctrine, where adopted, addresses the probabilistic-harm problem that the traditional more-likely-than-not rule cannot accommodate.

The case-building work requires careful extraction of the diagnostic timeline, identification of deviation points, and expert development of the alternative diagnostic pathway. AI-assisted record review compresses the timeline-reconstruction phase, leaving more time for the substantive expert work that drives outcomes.

Questions? Contact us at [email protected] or (856) 979-6525